Bacteremia, Carbapenem Resistant Bacterial Infection, Proteus Mirabilis Infection
Conditions
Keywords
Proteus mirabilis, bacteremia, carbapenem resistance, resistance mechanisms, PCR
Brief summary
This study aims to determine the clinical characteristics, risk factors, and resistance mechanisms of patients with carbapenem-resistant P. mirabilis bacteremia.Patients with P. mirabilis growth in blood culture samples sent to bacteriology laboratory between 2018 and 2021 were retrospectively analyzed. Patients meeting the inclusion criteria were divided into carbapenem-resistant and carbapenem- susceptible groups. The investigators recorded demographic data, clinical features, and laboratory findings. Resistance genes were investigated in carbapenem-resistant isolates using PCR.
Detailed description
Patients with P. mirabilis growth in blood culture who met the study criteria were divided into two groups as carbapenem susceptible and resistant according to carbapenem antibiogram results. Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group and patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group. Demographic characteristics of the patients, concomitant chronic diseases, Charlson comorbidity index (CCI), hospital and intensive care unit (ICU) hospitalization and number of days in the last year, history and type of invasive intervention in the last three months (surgical-invasive), history of antibiotic use in the last three months and types of antibiotics used (Penicillin, cephalosporin, quinolone, carbapenem, tigecycline, colistin, aminoglycoside), hospitalization unit, total length of hospitalization, sample collection unit, growth result and antibiogram, clinical and laboratory data of the day of growth, sepsis and septic shock evaluated according to systemic inflammatory response syndrome (SIRS) criteria, 30-day mortality and patient outcome information were recorded. Carbapenemase-producing gene regions were investigated by Polymerase Chain Reaction (PCR) in accessible samples of patients with carbapenem-resistant P. mirabilis growth in blood cultures.
Interventions
OTHERNon-Interventional Research
Non-Interventional Research
Sponsors
Dokuz Eylul University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Inpatients aged 18 years and older * P. mirabilis growth in blood cultures
Exclusion criteria
* Samples taken in emergency departments, outpatient clinics, day treatment units * Recurrent growths of the same patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Carbapenem Use | 1 year | number of patients using carbapenem before P. mirabilis growth in blood cultures |
| Intensive Care Units | 1 year | number of patients admission in ıntensive care units before P. mirabilis growth in blood cultures |
| Mortality | 30 days | number of patients who died |
| Length of hospital stay | 1 year | Length of hospital stay days |
| Presence of chronic disease | 1 year | number of patients with chronic disease |
Countries
Turkey (Türkiye)
Outcome results
None listed